Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
Submission to regulators globally is based on phase 2/3 studies of mRNA-1273 in young children
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Revolution Aspire CT System is manufactured at the company’s new plant launched under the government’s Production Linked Incentives (PLI) Scheme
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
The respective expertise of Lonza and Integral Molecular will benefit drug developers in the assessment of the risk for off-target binding and activation
It enables precise visualization and treatment access to the left heart
Trelegy is delivered via the innovative Ellipta inhaler that provides accurate dosing through its consistent dose delivery mechanism and is associated with less inhaler teaching time compared to other commonly used inhalers
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
The approval comes soon after Corbevax was given the nod for 12-15-year group
Subscribe To Our Newsletter & Stay Updated
